Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…Abstract Number: 1151 • 2014 ACR/ARHP Annual Meeting
Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States
Background/Purpose: Development of young rheumatology investigators is critical to the future of rheumatology. Beyond funding, the specific barriers to maintaining a career in rheumatology research…Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…Abstract Number: 1149 • 2014 ACR/ARHP Annual Meeting
Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis
Background/Purpose: Adherence is under consideration for quality reporting in a number of disease states. Published data on adherence of biologics reveal a wide range of…Abstract Number: 1148 • 2014 ACR/ARHP Annual Meeting
Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data
Background/Purpose: The identification of patients with recent-onset rheumatoid arthritis (RA) is often desirable to create inception cohorts of patients. We evaluated an approach to identify…Abstract Number: 1147 • 2014 ACR/ARHP Annual Meeting
Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA)
Background/Purpose: Government mandated dose tapering and withdrawal of biologic treatments for RA after achievement of sustained disease control is currently observed in Taiwan, the Netherlands,…Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting
Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…Abstract Number: 1143 • 2014 ACR/ARHP Annual Meeting
Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users
Background/Purpose: To identify the most and least important characteristics of rheumatoid arthritis (RA) treatment according to patients currently on biologic therapy. Methods: From the HealthCore…Abstract Number: 1142 • 2014 ACR/ARHP Annual Meeting
Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment
Background/Purpose: The risk of serious infections can vary across biologics. For example, in the 2-year AMPLE trial, serious infections occurred in 3.8% of SC abatacept-treated…Abstract Number: 1141 • 2014 ACR/ARHP Annual Meeting
Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression
Background/Purpose: We developed and validated a prognostic model to identify subjects with elevated risk of rapid radiographic progression (RRP). The objective of this study was…Abstract Number: 1160 • 2014 ACR/ARHP Annual Meeting
Annual Real-Practice Costs of Biologics for 200 Cases with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated By Tight Control and Treat to Target Strategy Permitting Dose Reduction
Background/Purpose To investigate annually real-practice costs of biologic therapy for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) cohort treated by tight control…Abstract Number: 1138 • 2014 ACR/ARHP Annual Meeting
Vasoactive Intestinal Peptide (VIP) Genetic Variants Determine VIP Serum Levels and Could be Used As a Prognosis Biomarker
Background/Purpose: VIP has shown immunoregulatory properties in assays performed with human or murine cells. VIP has demonstrated a therapeutic effect in a murine model of…Abstract Number: 1137 • 2014 ACR/ARHP Annual Meeting
Multiway Transcriptomic Analysis of Monocyte-Derived Dendritic Cells Discriminates Effects of Disease and of HLA-B27 in Spondyloarthritis
Background/Purpose Spondyloarthritis (SpA) etiology is largely multifactorial with a genetic component dominated by the long-known strong association with the HLA-B27 allele. This allele, however, is…
ACR Meeting Abstracts